Suppr超能文献

小儿血液透析患者的身材矮小与生长激素使用

Short stature and growth hormone use in pediatric hemodialysis patients.

作者信息

Gorman Gregory, Fivush Barbara, Frankenfield Diane, Warady Bradley, Watkins Sandra, Brem Andrew, Neu Alicia

机构信息

Johns Hopkins University School of Medicine, Baltimore, MD 21287-2535, USA.

出版信息

Pediatr Nephrol. 2005 Dec;20(12):1794-800. doi: 10.1007/s00467-005-1893-x. Epub 2005 Aug 18.

Abstract

End-stage renal disease (ESRD) causes growth retardation in children, and poor growth has been linked to worse outcomes. Recombinant human growth hormone (rhGH) can increase growth velocity and final adult height in pediatric ESRD patients. We aimed to identify clinical predictors of short stature (height standard deviation score (Ht SDS) <-1.88) and rhGH use in short stature pediatric hemodialysis patients. In 2002, the Centers for Medicare & Medicaid Services (CMS) Clinical Performances Measures (CPM) ESRD Project collected demographic, clinical and laboratory data as well as rhGH use on all in-center hemodialysis patients in the US aged <18 years. The odds ratios (OR) of short stature and rhGH use for individual predictors were determined by multivariate logistic regression modeling. Six-hundred and fifty-one (92%) of 710 eligible patients were included for analysis. Of these, 266 (41%) had Ht SDS <-1.88. After adjustment, short stature was predicted by congenital/urologic causes of ESRD ((OR 5.4; 95% confidence interval [CI], 2.1-13.8; p <0.001) in patients aged 10-14 years; (OR 2.8; 95% CI, 1.5-5.4; p <0.01) in patients aged 15-18 years) and increasing years on dialysis ((OR 1.2; 95% CI, 1.1-1.4; p <0.01) in patients aged 10-14 years; (OR 1.2; 95% CI, 1.1-1.4; p <0.001) in patients aged 15-18 years). Of 266 short stature patients, 214 (80.5%) had data on rhGH use. Of these, 80 (37%) had been prescribed rhGH. After adjustment, use of rhGH in short-stature patients was predicted by white race (OR 2.1; 95% CI, 1.1-4.0; p <0.05), increasing years on dialysis (OR 1.13; 95% CI, 1.05-1.22; p <0.01) and patients with BMI <16.6 kg/m(2) (OR 3.1; 95% CI, 1.2-8.4; p <0.05). Increasing age and level of intact parathyroid hormone were not associated with rhGH use among short stature patients. A significant proportion of pediatric hemodialysis patients have short stature. The majority of short-stature patients are not receiving rhGH. Patients with short stature who are white, have longer durations on dialysis and have lower BMI are more likely to receive rhGH.

摘要

终末期肾病(ESRD)会导致儿童生长发育迟缓,而生长发育不良与更差的预后相关。重组人生长激素(rhGH)可提高儿科ESRD患者的生长速度和最终成人身高。我们旨在确定身材矮小(身高标准差评分(Ht SDS)<-1.88)的临床预测因素以及身材矮小的儿科血液透析患者使用rhGH的情况。2002年,医疗保险和医疗补助服务中心(CMS)临床绩效指标(CPM)ESRD项目收集了美国所有年龄<18岁的中心血液透析患者的人口统计学、临床和实验室数据以及rhGH使用情况。通过多变量逻辑回归模型确定个体预测因素导致身材矮小和使用rhGH的比值比(OR)。710名符合条件的患者中有651名(92%)被纳入分析。其中,266名(41%)的Ht SDS<-1.88。调整后,10至14岁患者中,ESRD的先天性/泌尿系统病因可预测身材矮小(OR 5.4;95%置信区间[CI],2.1 - 13.8;p<0.001);15至18岁患者中,该病因预测身材矮小的OR为2.8(95% CI,1.5 - 5.4;p<0.01),且透析年限增加也可预测身材矮小(10至14岁患者中,OR 1.2;95% CI,1.1 - 1.4;p<0.01;15至18岁患者中,OR 1.2;95% CI,1.1 - 1.4;p<0.001)。在266名身材矮小的患者中,214名(80.5%)有rhGH使用数据。其中,80名(37%)曾被处方使用rhGH。调整后,身材矮小患者使用rhGH可由白人种族(OR 2.1;95% CI,1.1 - 4.0;p<0.05)、透析年限增加(OR 1.13;95% CI,1.05 - 1.22;p<0.01)以及体重指数(BMI)<16.6 kg/m²的患者(OR 3.1;95% CI,1.2 - 8.4;p<0.05)预测。年龄增加和甲状旁腺激素水平完整与身材矮小患者使用rhGH无关。相当一部分儿科血液透析患者身材矮小。大多数身材矮小的患者未接受rhGH治疗。白人、透析时间较长且BMI较低的身材矮小患者更有可能接受rhGH治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验